Lu-177 PSMA I&T Therapy for Prostate Cancer; Treatment Response, Treatment Toxicity, and Survival Results

Acar E., Sonmezer B., DEREBEK E., BEKİŞ R., ÖZDOĞAN Ö., Kaya G. C.

JOURNAL OF BASIC AND CLINICAL HEALTH SCIENCES, vol.3, no.3, pp.158-164, 2019 (ESCI) identifier

  • Publication Type: Article / Article
  • Volume: 3 Issue: 3
  • Publication Date: 2019
  • Doi Number: 10.30621/jbachs.2019.708
  • Journal Name: JOURNAL OF BASIC AND CLINICAL HEALTH SCIENCES
  • Journal Indexes: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
  • Page Numbers: pp.158-164
  • Keywords: PSMA, prostate cancer, radioligand therapy, mCRPC, theranostic, precision medicine, LU-177-PSMA-617 RADIOLIGAND THERAPY, RADIONUCLIDE THERAPY, SAFETY, CYCLES
  • Dokuz Eylül University Affiliated: Yes

Abstract

Purpose: This study aims to evaluate the serum PSA response, Ga-68 PSMA PET/CT response, hematological/nephrological toxicity and survival results of patients with castration-resistant metastatic prostate cancer who are receiving Lu-177 PSMA therapy.